CHEK2 and breast carcinoma: This finding is supported by previous reports of a 4% incidence rate for CHEK2*1100delC mutation in patients with premenopausal breast cancer (51) versus a 0.7% incidence rate in patients with postmenopausal breast cancer (52) in a population background of ~0.2% (calculated from ClinVar).